Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study
Objective: To assess differences in the new onset or worsening of baseline dyskinesia after the introduction of safinamide (SA) or opicapone (OP) as add-on therapy…Dopamine dysregulation syndrome in Parkinson’s disease controlled by safinamine
Objective: To describe a case of dopamine dysregulation syndrome managed by safinamide. Background: Dopamine dysregulation syndrome (DDS) is an uncommon non-motor symptom of Parkinson disease…SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation
Objective: This monocentric, randomised, blind study is designed to evaluate the effect of safinamide on motor and neuropsychiatric symptoms in the 3 month perioperative period…Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach
Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…Safinamide as an adjunct to Levodopa Therapy in Asian and Caucasian Patients with Parkinson’s Disease and Motor Fluctuations: A post-hoc Analysis of the SETTLE study
Objective: This study evaluated the efficacy and safety outcomes of safinamide as a levodopa adjunct therapy in Asian and Caucasian patients with Parkinson’s disease. Background:…Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide
Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…Improvement of movement disorder and neurodevelopment under selegiline in a CLTC deficient patient
Objective: We report the significative improvement on both movement disorder and neurodevelopment in a 5-year-old CLTC deficient patient treated with selegiline. Background: In 2019 we described a 30-year-old woman…SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.
Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…Safinamide adherence: the experience of the movement disorder unit of Trieste.
Objective: Describe the clinical experience with Safinamide and assess the patients’ adherence to this treatment in the movement disorders centre of Trieste-Italy. Background: Safinamide (Xadago®)…Effects of safinamide adjunct therapy on non-motor symptoms in patients with Parkinson’s disease: a post-hoc analysis of the Japanese Phase 2/3 study
Objective: To evaluate the efficacy of safinamide for mood and pain by a post-hoc analysis of the Japanese phase 2/3 double-blind study (JapicCTI-153056) in patients…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »